Global Metabolic Disorder Therapeutics Market to Reach $136.6 Billion by 2030
The global market for Metabolic Disorder Therapeutics estimated at US$73.4 Billion in the year 2022, is projected to reach a revised size of US$136.6 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2022-2030. Diabetes, one of the segments analyzed in the report, is projected to record 8.7% CAGR and reach US$91.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hypercholesterolemia segment is readjusted to a revised 6% CAGR for the next 8-year period.The U.S. Market is Estimated at $20 Billion, While China is Forecast to Grow at 13% CAGR
The Metabolic Disorder Therapeutics market in the U.S. is estimated at US$20 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$32.8 Billion by the year 2030 trailing a CAGR of 13% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 6.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.Select Competitors (Total 43 Featured) -
- AbbVie, Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen, Inc.
- AstraZeneca PLC
- Biocon Ltd.
- BioMarin Pharmaceutical, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla, Inc.
- CymaBay Therapeutics, Inc.
- Eli Lilly and Company
- Merck KgaA
- Novo Nordisk A/S
- Sanofi S.A.
- Shire PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Actelion Pharmaceuticals Ltd.
- Amgen, Inc.
- AstraZeneca PLC
- Biocon Ltd.
- BioMarin Pharmaceutical, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla, Inc.
- CymaBay Therapeutics, Inc.
- Eli Lilly and Company
- Merck KgaA
- Novo Nordisk A/S
- Sanofi S.A.
- Shire PLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 94 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 73.4 Billion |
Forecasted Market Value ( USD | $ 136.6 Billion |
Compound Annual Growth Rate | 8.1% |
Regions Covered | Global |